American Diabetes Association

TABLE 2

Data on IVGTT, hyperinsulinemic-euglycemic clamp, and indirect calorimetry in male study participants according to TCF7L2 rs7903146 genotype before and after bed rest

rs7903146	Before bed rest		After bed rest
rs7903146	TT/CT	CC	TT/CT	CC
n	21	17	21	17
Plasma glucose (mmol/l)
Basal	4.6 ± 0.4	4.6 ± 0.5	4.6 ± 0.4	4.6 ± 0.4
Insulin-stimulated state	5.0 ± 0.2	5.0 ± 0.2	5.0 ± 0.4	5.1 ± 0.4
Plasma insulin (pmol/l)*
Basal	26 ± 14	33 ± 23	30 ± 11	47 ± 27†‡
Insulin-stimulated state	745 ± 151	848 ± 258	821 ± 186	837 ± 192
Plasma glucagon (pmol/l)
Basal	6.7 ± 2.9	10.5 ± 4.3§	6.7 ± 3.6	9.4 ± 4.0†
HOMA-IR⁺ (10⁻⁶ × mmol⁻¹ · l⁻¹ · mmol⁻¹ · l⁻¹)*
Basal	5.3 ± 3.2	6.9 ± 5.2	6.1 ± 2.5	9.7 ± 5.8†‡
M value (mg · min⁻¹ · kg fat-free mass⁻¹)
Insulin-stimulated state	14.0 ± 1.9	14.0 ± 1.8	11.0 ± 1.7‡	10.0 ± 2.5‡
Glucose oxidation rate (mg · min⁻¹ · kg⁻¹ fat-free mass)
Basal	1.6 ± 0.4	1.4 ± 0.4	2.3 ± 0.9‡	2.8 ± 0.7‡
Insulin-stimulated state	4.2 ± 0.6	4.3 ± 0.6	4.5 ± 0.6	4.2 ± 0.7
Fat oxidation rate (mg · min⁻¹ · kg⁻¹ fat-free mass)
Basal	1.0 ± 0.3	1.1 ± 0.4	0.7 ± 0.4‡	0.5 ± 0.3‡
Insulin-stimulated state	0.1 ± 0.2	0.2 ± 0.4	−0.1 ± 0.3	0.1 ± 0.3
Nonoxidative glucose oxidation rate (mg · min⁻¹ · kg⁻¹ fat-free mass)
Insulin-stimulated state	9.9 ± 1.7	9.7 ± 2.0	6.5 ± 1.5‡	6.4 ± 1.8‡
FPIR (pmol⁻¹ · l⁻¹ · min⁻¹)*	1,559 ± 1,330	2,122 ± 1,464§	2,108 ± 1,339‡	3,503 ± 1,670†‡
Second-phase insulin response (pmol⁻¹ · l⁻¹ · min⁻¹)*	2,671 ± 2,954	2,618 ± 602	2,632 ± 1,012	4,960 ± 2,778†‡
AUC_total (pmol⁻¹ · l⁻¹ · min⁻¹)*	4,469 ± 3,905	5,032 ± 2,985	5,026 ± 2,190	8,946 ± 4,063†‡
D_i-peripheral (10⁻³ × pmol · ml⁻¹ · min⁻¹ · mg⁻¹ · min⁻¹ · kg fat-free mass⁻¹)*
Insulin-stimulated state	21.9 ± 20.4	30.4 ± 21.5§	24.0 ± 16.2	34.3 ± 17.7†
D_i-hepatic (pmol · l⁻¹ · min⁻¹ · μmol⁻¹ · min⁻¹ · kg fat-free mass⁻¹ · pmol⁻¹ · l⁻¹)*
Insulin-stimulated state	6.6 ± 6.4	14.2 ± 18.1‖	7.8 ± 5.6	9.4 ± 6.0

rs7903146	Before bed rest		After bed rest
rs7903146	TT/CT	CC	TT/CT	CC
n	21	17	21	17
Plasma glucose (mmol/l)
Basal	4.6 ± 0.4	4.6 ± 0.5	4.6 ± 0.4	4.6 ± 0.4
Insulin-stimulated state	5.0 ± 0.2	5.0 ± 0.2	5.0 ± 0.4	5.1 ± 0.4
Plasma insulin (pmol/l)*
Basal	26 ± 14	33 ± 23	30 ± 11	47 ± 27†‡
Insulin-stimulated state	745 ± 151	848 ± 258	821 ± 186	837 ± 192
Plasma glucagon (pmol/l)
Basal	6.7 ± 2.9	10.5 ± 4.3§	6.7 ± 3.6	9.4 ± 4.0†
HOMA-IR⁺ (10⁻⁶ × mmol⁻¹ · l⁻¹ · mmol⁻¹ · l⁻¹)*
Basal	5.3 ± 3.2	6.9 ± 5.2	6.1 ± 2.5	9.7 ± 5.8†‡
M value (mg · min⁻¹ · kg fat-free mass⁻¹)
Insulin-stimulated state	14.0 ± 1.9	14.0 ± 1.8	11.0 ± 1.7‡	10.0 ± 2.5‡
Glucose oxidation rate (mg · min⁻¹ · kg⁻¹ fat-free mass)
Basal	1.6 ± 0.4	1.4 ± 0.4	2.3 ± 0.9‡	2.8 ± 0.7‡
Insulin-stimulated state	4.2 ± 0.6	4.3 ± 0.6	4.5 ± 0.6	4.2 ± 0.7
Fat oxidation rate (mg · min⁻¹ · kg⁻¹ fat-free mass)
Basal	1.0 ± 0.3	1.1 ± 0.4	0.7 ± 0.4‡	0.5 ± 0.3‡
Insulin-stimulated state	0.1 ± 0.2	0.2 ± 0.4	−0.1 ± 0.3	0.1 ± 0.3
Nonoxidative glucose oxidation rate (mg · min⁻¹ · kg⁻¹ fat-free mass)
Insulin-stimulated state	9.9 ± 1.7	9.7 ± 2.0	6.5 ± 1.5‡	6.4 ± 1.8‡
FPIR (pmol⁻¹ · l⁻¹ · min⁻¹)*	1,559 ± 1,330	2,122 ± 1,464§	2,108 ± 1,339‡	3,503 ± 1,670†‡
Second-phase insulin response (pmol⁻¹ · l⁻¹ · min⁻¹)*	2,671 ± 2,954	2,618 ± 602	2,632 ± 1,012	4,960 ± 2,778†‡
AUC_total (pmol⁻¹ · l⁻¹ · min⁻¹)*	4,469 ± 3,905	5,032 ± 2,985	5,026 ± 2,190	8,946 ± 4,063†‡
D_i-peripheral (10⁻³ × pmol · ml⁻¹ · min⁻¹ · mg⁻¹ · min⁻¹ · kg fat-free mass⁻¹)*
Insulin-stimulated state	21.9 ± 20.4	30.4 ± 21.5§	24.0 ± 16.2	34.3 ± 17.7†
D_i-hepatic (pmol · l⁻¹ · min⁻¹ · μmol⁻¹ · min⁻¹ · kg fat-free mass⁻¹ · pmol⁻¹ · l⁻¹)*
Insulin-stimulated state	6.6 ± 6.4	14.2 ± 18.1‖	7.8 ± 5.6	9.4 ± 6.0

Data are means ± SD.

*Log-transformed data.

†Significant difference between the TT/CT and CC groups after bed rest, P < 0.05.

‡Significant difference before versus after bed rest; P < 0.05. Significant difference between the TT/CT and CC groups before bed rest,

§P < 0.05 and

‖P = 0.05.

View Large

This Feature Is Available To Subscribers Only